Literature DB >> 17161242

Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study.

Gianluca Campo1, Marco Valgimigli, Donato Gemmati, Gianfranco Percoco, Silvia Tognazzo, Giordano Cicchitelli, Linda Catozzi, Patrizia Malagutti, Maurizio Anselmi, Corrado Vassanelli, Gianluigi Scapoli, Roberto Ferrari.   

Abstract

OBJECTIVES: The purpose of this study was to evaluate the value of platelet reactivity (PR) in predicting the response to treatment and outcome in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention assisted by glycoprotein (GP) IIb/IIIa inhibition.
BACKGROUND: There is limited prognostic information on the role of spontaneous or drug-modulated PR in STEMI patients.
METHODS: The PR was measured with Platelet Function Analyzer (PFA)-100 and light transmission aggregometry (LTA) using adenosine diphosphate as agonist in 70 consecutive STEMI patients at entry (PR-T0), 10 min after GP IIb/IIIa bolus (PR-T1), and discharge (PR-T2) and in 30 stable angina (SA) patients (PR-SA). Complete platelet inhibition (CPI) was based on closure time >300 s by PFA-100 and percentage inhibition of platelet aggregation >95% by LTA. Clinical, electrocardiographic, and angiographic responses to treatment during 1-year follow-up were collected.
RESULTS: According to both techniques, PR-T0 was higher than: 1) PR-T2 and PR-SA; 2) in those without CPI at T1; and 3) in patients with final Thrombolysis In Myocardial Infarction (TIMI) flow grade <3. The PR-T0 assessed with PFA-100 correlated with: 1) corrected TIMI frame count (r = -0.6, p < 0.001); 2) ST-segment resolution (r = 45, p < 0.001); and 3) creatine kinase-MB (r = -0.47, p < 0.001). At 1 year, patients with high PR-T0 showed an adjusted 5- to 11-fold increase in the risk of death, reinfarction, and target vessel revascularization (hazard ratio [HR] 11, 95% confidence interval [CI] 1.5 to 78 [p = 0.02] in PFA-100; HR 5.2, 95% CI 1.1 to 23 [p = 0.03] in LTA).
CONCLUSIONS: The PR at entry affects response to GP IIb/IIIa inhibition, mechanical treatment, and long-term outcome in STEMI patients undergoing primary intervention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17161242     DOI: 10.1016/j.jacc.2005.12.085

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  19 in total

1.  The in vitro effects of verbascoside on human platelet aggregation.

Authors:  Gianluca Campo; Jlenia Marchesini; Laura Bristot; Monia Monti; Stefania Gambetti; Rita Pavasini; Alberto Pollina; Roberto Ferrari
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Gene expression profiling in peripheral blood nuclear cells in patients with refractory ischaemic end-stage heart failure.

Authors:  S Szmit; M Jank; H Maciejewski; M Grabowski; R Glowczynska; A Majewska; K J Filipiak; T Motyl; G Opolski
Journal:  J Appl Genet       Date:  2010       Impact factor: 3.240

Review 3.  Triple antiplatelet therapy in acute coronary syndromes.

Authors:  Marco Valgimigli; Monica Minarelli
Journal:  Drugs       Date:  2011-09-10       Impact factor: 9.546

4.  Polymorphism in the protease-activated receptor-4 gene region associates with platelet activation and perioperative myocardial injury.

Authors:  Jochen D Muehlschlegel; Tjörvi E Perry; Kuang-Yu Liu; Amanda A Fox; Shane A Smith; Peter Lichtner; Charles D Collard; Stanton K Shernan; John H Hartwig; Simon C Body; Karin M Hoffmeister
Journal:  Am J Hematol       Date:  2012-01-07       Impact factor: 10.047

5.  Outcome of Triple Antiplatelet Therapy Including Cilostazol in Elderly Patients with ST-Elevation Myocardial Infarction who Underwent Primary Percutaneous Coronary Intervention: Results from the INTERSTELLAR Registry.

Authors:  Ho-Jun Jang; Sang-Don Park; Hyun Woo Park; Jon Suh; Pyung Chun Oh; Jeonggeun Moon; Kyounghoon Lee; Woong Chol Kang; Sung Woo Kwon; Tae-Hoon Kim
Journal:  Drugs Aging       Date:  2017-06       Impact factor: 3.923

Review 6.  Aspirin dosing frequency in the primary and secondary prevention of cardiovascular events.

Authors:  Joonseok Kim; Richard C Becker
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

Review 7.  Defining the role of platelet glycoprotein receptor inhibitors in STEMI: focus on tirofiban.

Authors:  Arnoud W J van 't Hof; Marco Valgimigli
Journal:  Drugs       Date:  2009       Impact factor: 9.546

8.  Factors related to progression of middle cerebral artery stenosis determined using transcranial Doppler ultrasonograhy.

Authors:  Hyung-Won Jeon; Jae-Kwan Cha
Journal:  J Thromb Thrombolysis       Date:  2007-06-01       Impact factor: 2.300

9.  Aspirin resistance.

Authors:  Khaled Mansour; Ali T Taher; Khaled M Musallam; Samir Alam
Journal:  Adv Hematol       Date:  2009-04-14

10.  Abciximab: a reappraisal of its use in coronary care.

Authors:  Marco Valgimigli; Gianluca Campo; Matteo Tebaldi; Roberto Carletti; Chiara Arcozzi; Roberto Ferrari; Gianfranco Percoco
Journal:  Biologics       Date:  2008-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.